News

Apr 23, 2026

2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations

➞

Apr 23, 2026

Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer

➞

Apr 22, 2026

Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine

➞

Apr 21, 2026

Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time

➞

Apr 16, 2026

Mabwell Establishes a Licensing and Commercialization Agreement for Denosumab Biosimilars in Malaysian Market

➞

Apr 15, 2026

Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)

➞

Apr 15, 2026

Global First | NMPA Accepts IND Application for Mabwell’s Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311

➞

Apr 14, 2026

SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial.

➞

Mar 25, 2026

Mabwell Established a Licensing and Commercialization Agreement of Denosumab Biosimilars for Vietnamese Market

➞

Mar 12, 2026

Dr. Liu Datao Attends "Focus on the Two Sessions · 2026 6th Ophthalmology Summit"

➞